NZ590326A - Antagonists of activin-actriia and uses for increasing red blood cell levels - Google Patents

Antagonists of activin-actriia and uses for increasing red blood cell levels

Info

Publication number
NZ590326A
NZ590326A NZ590326A NZ59032609A NZ590326A NZ 590326 A NZ590326 A NZ 590326A NZ 590326 A NZ590326 A NZ 590326A NZ 59032609 A NZ59032609 A NZ 59032609A NZ 590326 A NZ590326 A NZ 590326A
Authority
NZ
New Zealand
Prior art keywords
anaemia
actriia
activin
antagonists
red blood
Prior art date
Application number
NZ590326A
Other languages
English (en)
Inventor
Matthew L Sherman
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Priority to NZ602471A priority Critical patent/NZ602471A/en
Publication of NZ590326A publication Critical patent/NZ590326A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ590326A 2008-06-26 2009-06-26 Antagonists of activin-actriia and uses for increasing red blood cell levels NZ590326A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ602471A NZ602471A (en) 2008-06-26 2009-06-26 Antagonists of activin-actriia and uses for increasing red blood cell levels

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13336808P 2008-06-26 2008-06-26
PCT/US2009/003838 WO2009158033A2 (en) 2008-06-26 2009-06-26 Antagonists of activin-actriia and uses for increasing red blood cell levels

Publications (1)

Publication Number Publication Date
NZ590326A true NZ590326A (en) 2013-05-31

Family

ID=41445146

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ590326A NZ590326A (en) 2008-06-26 2009-06-26 Antagonists of activin-actriia and uses for increasing red blood cell levels
NZ602471A NZ602471A (en) 2008-06-26 2009-06-26 Antagonists of activin-actriia and uses for increasing red blood cell levels

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ602471A NZ602471A (en) 2008-06-26 2009-06-26 Antagonists of activin-actriia and uses for increasing red blood cell levels

Country Status (10)

Country Link
EP (4) EP2318028B1 (enExample)
JP (8) JP5773868B2 (enExample)
KR (4) KR20210047374A (enExample)
CN (2) CN107252486B (enExample)
AU (4) AU2009262968A1 (enExample)
CA (3) CA2729054C (enExample)
DK (1) DK2318028T3 (enExample)
ES (2) ES2852699T3 (enExample)
NZ (2) NZ590326A (enExample)
WO (2) WO2009158033A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2314617B1 (en) 2004-07-23 2015-06-24 Acceleron Pharma Inc. ActRII receptor polypeptides
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
EA201692543A1 (ru) 2005-11-23 2017-08-31 Акселерон Фарма Инк. Антагонисты активина-actriia и их применение для стимулирования роста кости
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
MX354099B (es) 2007-02-01 2018-02-13 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TWI432449B (zh) 2007-02-02 2014-04-01 Acceleron Pharma Inc 衍生自ＡｃｔＲＩＩＢ的變體與其用途
KR20160129095A (ko) 2007-02-09 2016-11-08 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
CA2699936A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
PT2340031T (pt) 2008-08-14 2019-07-25 Acceleron Pharma Inc Armadilhas de gdf para uso no tratamento de anemia
US8138142B2 (en) 2009-01-13 2012-03-20 Acceleron Pharma Inc. Methods for increasing adiponectin in a patient in need thereof
CN102482339B (zh) 2009-06-08 2015-06-17 阿塞勒隆制药公司 用于增加产热脂肪细胞的方法
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
RU2642302C1 (ru) * 2009-08-13 2018-01-24 Акселерон Фарма Инк. Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов
AU2015203400A1 (en) * 2009-08-13 2015-07-16 Acceleron Pharma Inc. Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels
WO2011063018A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
US20120121576A1 (en) 2010-11-08 2012-05-17 Jasbir Seehra Actriia binding agents and uses thereof
GR1007832B (el) * 2011-11-21 2013-02-14 Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
US9809636B2 (en) * 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
CN112957462A (zh) * 2012-10-24 2021-06-15 细胞基因公司 用于治疗贫血的方法
MX366336B (es) 2012-11-02 2019-07-05 Celgene Corp Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros.
AU2014209178B2 (en) 2013-01-25 2018-11-08 Takeda Pharmaceutical Company Limited Follistatin in treating Duchenne muscular dystrophy
AP2016009549A0 (en) * 2014-04-18 2016-11-30 Acceleron Pharma Inc Methods for increasing red blood cell levels and treating sickle-cell disease
KR102305109B1 (ko) * 2014-06-04 2021-09-27 악셀레론 파마 인코포레이티드 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물
BR112016029226A2 (pt) 2014-06-13 2017-10-17 Acceleron Pharma Inc métodos e composições para o tratamento de úlceras
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
FI3227675T3 (fi) 2014-12-03 2023-05-25 Celgene Corp Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi
AU2016246602B2 (en) * 2015-04-06 2020-11-19 Acceleron Pharma Inc. Single-arm type I and type II receptor fusion proteins and uses thereof
RS61881B1 (sr) 2015-04-22 2021-06-30 Biogen Ma Inc Novi hibridni actriib proteini zamke za ligand za lečenje bolesti gubljenja mišića
JP7072507B2 (ja) 2015-11-23 2022-05-20 アクセルロン ファーマ インコーポレイテッド 眼の障害を処置するための方法
US20170306027A1 (en) 2016-04-06 2017-10-26 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
MX2019001043A (es) 2016-07-27 2019-09-26 Acceleron Pharma Inc Metodos y composiciones para el tratamiento de la mielofibrosis.
JP7280182B2 (ja) 2016-10-05 2023-05-23 アクセルロン ファーマ インコーポレイテッド バリアントＡｃｔＲＩＩＢタンパク質およびその使用
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
JP7051846B2 (ja) * 2016-11-10 2022-04-11 ケロス セラピューティクス インコーポレイテッド アクチビンＩＩａ型受容体変異体および同変異体を含む医薬組成物
JP7258021B2 (ja) 2017-11-09 2023-04-14 ケロス セラピューティクス インコーポレイテッド アクチビンＩＩａ型受容体変異体を含む医薬組成物
KR20200109330A (ko) 2018-01-12 2020-09-22 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법
CA3098679A1 (en) * 2018-05-09 2019-11-14 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
CN113015743B (zh) * 2018-11-15 2025-06-24 三菱化学株式会社 改变型激活素a
KR20220049568A (ko) * 2019-08-22 2022-04-21 더 리전츠 오브 더 유니버시티 오브 캘리포니아 엔젤만 증후군의 치료를 위한 ube3a
WO2021189010A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
CA3228901A1 (en) * 2021-09-03 2023-03-09 Chris Xiangyang Lu Anti-acvr2a antibodies and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1265208A (en) 1915-09-07 1918-05-07 Edward C Kahn Liquid-fuel burner.
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
WO1992004913A1 (en) * 1990-09-13 1992-04-02 Children's Hospital Medical Center Of Northern California Method for increasing red blood cell production by treatment with activin or activin-related peptides
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
JPH11502717A (ja) 1995-04-11 1999-03-09 ザ ジェネラル ホスピタル コーポレーション 逆ツーハイブリッドシステム
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
US6953662B2 (en) * 1997-08-29 2005-10-11 Human Genome Sciences, Inc. Follistatin-3
CA2302525A1 (en) 1997-08-29 1999-03-04 Human Genome Sciences, Inc. Follistatin-3
US6468543B1 (en) * 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
AU1325102A (en) 2000-10-16 2002-04-29 Phylos Inc Protein scaffolds for antibody mimics and other binding proteins
ATE472609T1 (de) 2001-04-26 2010-07-15 Amgen Mountain View Inc Kombinatorische bibliotheken von monomerdomänen
IL159015A0 (en) * 2001-05-25 2004-05-12 Genset Sa Polypeptides, their preparation and use
US6855344B2 (en) * 2001-07-17 2005-02-15 Integrated Chinese Medicine Holdings, Ltd. Compositions and methods for prostate and kidney health and disorders, an herbal preparation
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
US20070184052A1 (en) * 2003-05-09 2007-08-09 Lin Herbert Y Soluble tgf-b type III receptor fusion proteins
US20070135336A1 (en) 2003-09-15 2007-06-14 De Kretser David Follistatin isoforms and uses thereof
JP4688483B2 (ja) 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
EP2314617B1 (en) * 2004-07-23 2015-06-24 Acceleron Pharma Inc. ActRII receptor polypeptides
JP2008509927A (ja) * 2004-08-12 2008-04-03 ワイス Ｇｄｆ−８阻害剤を使用する、糖尿病、肥満、および心臓血管疾患のための併用療法
EP1824796A4 (en) 2004-11-16 2010-02-17 Avidia Res Inst PROTEIN SKELETONS AND USES THEREOF
EA201692543A1 (ru) 2005-11-23 2017-08-31 Акселерон Фарма Инк. Антагонисты активина-actriia и их применение для стимулирования роста кости
EA200802213A1 (ru) * 2006-05-09 2009-10-30 Химекуэст Фармасьютикалз, Инк. Способы лечения заболеваний крови
SI2043802T1 (sl) * 2006-07-13 2012-11-30 Basf Se Termoplastične mase ki vsebujejo vezalna sredstva za proizvodnjo kovinskih kalupov
ES2382993T3 (es) * 2006-07-21 2012-06-15 Lyne Laboratories, Inc. Composición líquida de acetato de calcio
WO2008030367A2 (en) 2006-09-01 2008-03-13 The General Hospital Corporation Selective myostatin inhibitors
US7547781B2 (en) * 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
EP2124999B1 (en) * 2006-12-18 2012-10-03 Acceleron Pharma, Inc. Activin-actrii antagonists and uses for treating anemia
TWI432449B (zh) 2007-02-02 2014-04-01 Acceleron Pharma Inc 衍生自ＡｃｔＲＩＩＢ的變體與其用途
KR20160129095A (ko) 2007-02-09 2016-11-08 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
CA2699936A1 (en) * 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
DE102008016742B4 (de) * 2008-03-31 2010-01-14 Thyssenkrupp Presta Ag Lenksäule für ein Kraftfahrzeug

Also Published As

Publication number Publication date
KR20110031951A (ko) 2011-03-29
AU2016203098B2 (en) 2018-03-08
JP2018184484A (ja) 2018-11-22
KR102024444B1 (ko) 2019-09-23
JP2011526626A (ja) 2011-10-13
KR20170038937A (ko) 2017-04-07
WO2009158015A3 (en) 2010-03-04
EP2303917A2 (en) 2011-04-06
ES2852699T3 (es) 2021-09-14
JP6643432B2 (ja) 2020-02-12
JP2020041002A (ja) 2020-03-19
CA2729098A1 (en) 2009-12-30
JP5773868B2 (ja) 2015-09-02
KR20190049912A (ko) 2019-05-09
JP2015187180A (ja) 2015-10-29
EP2318028A4 (en) 2012-08-15
JP2014088438A (ja) 2014-05-15
ES2791699T3 (es) 2020-11-05
JP2017036331A (ja) 2017-02-16
EP2318028B1 (en) 2020-02-19
EP2303917B1 (en) 2020-11-11
EP2318028A2 (en) 2011-05-11
WO2009158033A3 (en) 2010-04-01
WO2009158033A2 (en) 2009-12-30
AU2016203098A1 (en) 2016-06-02
WO2009158015A2 (en) 2009-12-30
CA2729054C (en) 2019-09-03
KR20210047374A (ko) 2021-04-29
CA3049354A1 (en) 2009-12-30
CN107252486A (zh) 2017-10-17
EP2303917A4 (en) 2012-01-25
AU2020220046A1 (en) 2020-09-03
CA2729054A1 (en) 2009-12-30
NZ602471A (en) 2014-10-31
CA2729098C (en) 2018-02-13
EP3620795A1 (en) 2020-03-11
AU2018204105A1 (en) 2018-06-28
EP3804746A1 (en) 2021-04-14
DK2318028T3 (da) 2020-05-04
JP2019006805A (ja) 2019-01-17
CN107252486B (zh) 2021-10-22
AU2009262968A1 (en) 2009-12-30
CN102131515B (zh) 2017-06-27
CN102131515A (zh) 2011-07-20
HK1245147A1 (zh) 2018-08-24
JP2022023184A (ja) 2022-02-07

Similar Documents

Publication Publication Date Title
NZ590326A (en) Antagonists of activin-actriia and uses for increasing red blood cell levels
WO2009106991A3 (en) Pyridazine derivatives and their use as therapeutic agents in the treatment of skin disorders
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
WO2012068531A3 (en) Novel compositions and uses of anti-hypertension agents for cancer therapy
WO2010068866A3 (en) Therapeutic particles suitable for parenteral administration and methods of making and using same
TW200616627A (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
EA201300556A1 (ru) Аминоспиртзамещенные производные 2,3-дигидроимидазо[1,2-с] хиназолина, пригодные для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом
HRP20140745T1 (hr) Uporaba amisulprida za lijeäśenje kemoterapijom izazvane muäśnine i povraä†anja
BR112013004917A2 (pt) terapias de células tronco alogênicas sistêmicas para tratamento de doenças em animais.
WO2007134245A3 (en) Elastin-like polymer delivery vehicles
MX2010006739A (es) Compuestos pirido[2,3-b]pirazina-8-sustituidos y su uso.
MY158100A (en) 6,9-disubstituted purine derivatives and their use for treating skin
AU2010300611A8 (en) Hematopoietic stem cells for use in the treatment of a kidney injury
NZ606825A (en) Methods and compositions for treating complement-associated disorders
MX2010004074A (es) Combinacion 059.
NZ588853A (en) Compositions and methods for treating and diagnosing asthma
EP4467160A3 (en) Stabilized liquid and lyophilized adamts13 formulations
NZ592641A (en) 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine, its salts, and uses in medical treatment
WO2012021818A3 (en) Ggf2 and methods of use
WO2014160216A3 (en) Dual targeting anticancer agents
WO2007120484A3 (en) Use of inositol-tripyrophosphate in treating tumors and diseases
WO2009016488A3 (en) Compositions comprising tetracyclic antidepressants for treatment of cancer and related methods
PL1778833T3 (pl) Sposoby stosowania komórek regeneracyjnych w celu przyspieszania gojenia się ran
EP2156843A3 (de) Verwendung von niedrig dosiertem Erythropoietin zur Behandlung von akuter oder chronischer Niereninsuffizienz und zur Behandlung von Wunden
GB0718878D0 (en) Photodynamic Theraphy and diagnosis

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE TITLE HAS BEEN CORRECTED TO TITLE: ANTAGONISTS OF ACTIVIN-ACTRIIA AND USES FOR INCREASING RED BLOOD CELL LEVELS; FILING DATE: 07 JAN 2011; STATUS: REJECTED; TITLE: ANTAGONISTS OF ACTIVIN-ACTRIIA AND USES FOR INCREASING RED BLOOD CELL LEVELS; FILING DATE: 19 SEP 2012; STATUS: PROPOSED; TITLE: ANTAGONISTS OF ACTIVIN-ACTRIIA AND USES FOR INCREASING RED BLOOD CELL LEVELS; FILING DATE: 12 APR 2011; STATUS: REJECTED;

Effective date: 20130321

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 26 JUN 2016 BY SHELSTON IP

Effective date: 20130903

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 JUN 2017 BY COMPUTER PACKAGES INC

Effective date: 20160601

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 JUN 2018 BY COMPUTER PACKAGES INC

Effective date: 20170531

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 JUN 2019 BY COMPUTER PACKAGES INC

Effective date: 20180531

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 JUN 2020 BY COMPUTER PACKAGES INC

Effective date: 20190531

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 JUN 2021 BY COMPUTER PACKAGES INC

Effective date: 20200603

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 JUN 2022 BY IPAN GMBH

Effective date: 20210614

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 JUN 2023 BY IPAN GMBH

Effective date: 20220613

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 JUN 2024 BY THOMSON REUTERS

Effective date: 20230501

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 JUN 2025 BY THOMSON REUTERS

Effective date: 20240502

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 JUN 2026 BY THOMSON REUTERS

Effective date: 20250501